Acute Bacterial Rhinosinusitis in Adults – Evidence‑Based Recommendations

Diagnostic Criteria for Acute Bacterial Rhinosinusitis (ABRS)

• Persistent nasal or facial symptoms for ≥ 10 days without improvement indicate ABRS. 1, 2
• Severe presentation—high fever (> 39 °C) plus purulent nasal discharge or facial pain for ≥ 3 consecutive days—supports bacterial etiology. 1, 2
• “Double worsening” (initial improvement followed by symptom relapse 5–10 days after onset) is a hallmark of bacterial infection. 1, 2

Initial Management Strategy

• Watchful waiting (no immediate antibiotics) is appropriate for any adult with uncomplicated ABRS when reliable follow‑up within 7 days can be ensured. 3, 4, 2
• Spontaneous resolution occurs in 80–90 % of such patients within 7–15 days without antibiotics. 3

First‑Line Antibiotic Selection

Low‑Risk Patients (No Resistance Risk Factors)

• Standard‑dose amoxicillin (single agent) is preferred for uncomplicated ABRS, targeting Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. 5, 6

Patients with Resistance Risk Factors (High‑Risk)

• High‑dose amoxicillin‑clavulanate (2 g twice daily) should replace standard amoxicillin when any of the following are present:
  (All risk factors supported by the same evidence source.) 7

Updated 2025 Guideline Recommendation

• The 2025 update advises amoxicillin with or without clavulanate as the first‑line regimen for most adults, reflecting the need to cover β‑lactamase‑producing organisms. 2

Penicillin‑Allergic Adults

• Acceptable alternatives: doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin). 7
• For non‑type I hypersensitivity, a combination of clindamycin plus a third‑generation oral cephalosporin (e.g., cefixime or cefpodoxime) may be used. 7

Duration of Therapy

• 5–7 days of therapy is sufficient for uncomplicated ABRS in adults. 3
• This short course is as effective as 10–14‑day regimens and significantly reduces adverse effects. 3
• Some experts suggest extending treatment until the patient is symptom‑free plus an additional 7 days, but supporting evidence is limited. 5, 6

Reassessment and Management of Treatment Failure

• Reevaluate patients 72 hours after initiating therapy if symptoms worsen or fail to improve.
• If no improvement after 3–5 days of initial amoxicillin, switch to high‑dose amoxicillin‑clavulanate. 5
• Alternative second‑line agents include cefuroxime, cefpodoxime, cefdinir, or a respiratory fluoroquinolone. 5, 8

Adjunctive Symptomatic Therapies

• Intranasal saline irrigation helps clear mucus and relieve symptoms. 1
• Analgesics (acetaminophen or ibuprofen) are recommended for pain and fever control. 3, 4
• Intranasal corticosteroids may modestly reduce symptoms after 15 days of use (Number Needed to Treat = 14). 3, 4
• Oral or topical decongestants can be used for nasal congestion; topical agents should be limited to ≤ 3 days to avoid rebound congestion. 3, 4
• Routine antihistamines or oral corticosteroids are not advised, as they do not improve symptoms and add unnecessary side effects. 3, 4

Common Pitfalls and Safety Considerations

All statements are derived from peer‑reviewed sources indicated by the citation IDs.

First‑Line Antibiotic Management for Acute Bacterial Sinusitis

Adults – No Risk Factors for Resistance

• Standard‑dose amoxicillin alone is recommended for uncomplicated acute bacterial rhinosinusitis in adults without resistance risk factors, based on its effectiveness, safety, low cost, and narrow microbiologic spectrum. (American Academy of Otolaryngology–Head and Neck Surgery) [9][10]

Adults – Presence of Resistance Risk Factors

• High‑dose amoxicillin‑clavulanate (2 g twice daily) should be used when any of the following are present: recent antibiotic use (within 1 month), moderate‑to‑severe or protracted symptoms, age > 65 years, comorbidities (diabetes, chronic cardiac/hepatic/renal disease, immunocompromise), residence in regions with >10 % penicillin‑nonsusceptible Streptococcus pneumoniae, close contact with daycare facilities, or recent hospitalization. (American Academy of Otolaryngology–Head and Neck Surgery) [11][12]

Pediatric Patients – Age ≥ 2 Years

• Standard‑dose amoxicillin (≈ 45 mg/kg/day in two divided doses) is appropriate for uncomplicated mild‑to‑moderate sinusitis. (American Academy of Pediatrics) 10
• In communities where >10 % of S. pneumoniae isolates are penicillin‑nonsusceptible, high‑dose amoxicillin (≈ 80–90 mg/kg/day, max 2 g per dose) should be used. (American Academy of Pediatrics) 10

Pediatric Patients – Age < 2 Years or High‑Risk Situations

• For children younger than 2 years who attend daycare, have recent antibiotic exposure, or present with moderate‑to‑severe illness, high‑dose amoxicillin‑clavulanate (≈ 80–90 mg/kg/day amoxicillin component + 6.4 mg/kg/day clavulanate, divided twice daily) is recommended. (American Academy of Pediatrics) 10

Penicillin‑Allergic Patients – Adults

• Doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) are acceptable alternatives. (American Academy of Otolaryngology–Head and Neck Surgery) 11
• For patients with non‑type I hypersensitivity, a combination of clindamycin plus a third‑generation oral cephalosporin (cefixime or cefpodoxime) may be used. (American Academy of Otolaryngology–Head and Neck Surgery) 11

Penicillin‑Allergic Patients – Children

• Cefdinir, cefuroxime, or cefpodoxime are suitable oral options. (American Academy of Pediatrics) 13
• Second‑ and third‑generation cephalosporins carry negligible risk of serious allergic reaction in patients with penicillin allergy. (American Academy of Pediatrics) [14][15]

Antibiotics Not Recommended as First‑Line

• Macrolides (azithromycin, clarithromycin) and trimethoprim‑sulfamethoxazole should be avoided because of high resistance rates: macrolide‑resistant S. pneumoniae exceeds 40 % in the United States, and TMP‑SMX resistance is ~50 % for S. pneumoniae and ~27 % for H. influenzae. (American Academy of Otolaryngology–Head and Neck Surgery) 11

Duration of Therapy

• Adults: 5–7 days of therapy is as effective as a 10‑day course and reduces adverse events. (American Academy of Otolaryngology–Head and Neck Surgery) 11
• Children: 10–14 days, or continue for 7 days after symptom resolution, is recommended. (American Academy of Pediatrics) 10
• Shorter courses (5 days) lower the incidence of adverse events without compromising efficacy. (American Academy of Otolaryngology–Head and Neck Surgery) 11

Special Considerations

• Frontal, ethmoidal, or sphenoidal sinusitis: consider a respiratory fluoroquinolone (levofloxacin or moxifloxacin) due to higher risk of complications. (Clinical Microbiology and Infection) [16][17]18
• Vomiting children or those unable to take oral medication: give a single dose of ceftriaxone 50 mg/kg IV/IM, then switch to oral therapy after clinical improvement. (American Academy of Pediatrics) 10

Common Pitfalls to Avoid

• Do not prescribe antibiotics for viral rhinosinusitis lasting <10 days without clinical worsening. (Clinical Infectious Diseases) 12
• Reassess at 72 hours if symptoms worsen or fail to improve; consider changing or initiating antibiotics at that point. (American Family Physician; Pediatrics; Clinical Infectious Diseases) [13][15]12
• Adverse events occur in 15–40 % of patients receiving antibiotics for sinusitis, most commonly gastrointestinal symptoms. (American Academy of Otolaryngology–Head and Neck Surgery) 11

Antibiotic Management of Uncomplicated Acute Bacterial Sinusitis in Adults

When Antibiotics Are Indicated

• Watchful waiting is appropriate when reliable follow‑up within 7 days can be ensured, because 80–90 % of patients improve spontaneously without antimicrobial therapy. American Academy of Otolaryngology–Head and Neck Surgery recommends this approach. 19
• Antibiotics should be reserved for patients who have persistent symptoms for ≥10 days without improvement. This threshold is supported by guideline evidence. [19][20]
• Severe presentations—defined as a temperature > 39 °C together with purulent nasal discharge or facial pain lasting ≥3 consecutive days—warrant immediate antibiotic therapy. 20

First‑Line Antibiotic Selection

Standard‑Dose Amoxicillin (Low‑Risk Patients)

• Amoxicillin alone (standard dose) is the recommended first‑line agent for uncomplicated cases in adults without risk factors for resistant organisms. American Academy of Otolaryngology–Head and Neck Surgery gives a strong recommendation. 19
• This regimen targets the three predominant pathogens (Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis). 19
• Amoxicillin is favored because of its proven effectiveness, safety, tolerability, low cost, and narrow microbiologic spectrum. 19

High‑Dose Amoxicillin‑Clavulanate (High‑Risk Patients)

• When risk factors for resistant organisms are present, high‑dose amoxicillin‑clavulanate (2 g twice daily) is advised. The clavulanate component inhibits β‑lactamase‑producing H. influenzae (≈ 40 % of resistant isolates) and M. catarrhalis (≈ 100 % of resistant isolates). American Academy of Pediatrics provides moderate‑quality evidence for this coverage benefit. 21

Alternatives for Documented Penicillin Allergy

• For patients with a confirmed penicillin allergy, doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) are recommended first‑line options. 19

Duration of Therapy

• Treat uncomplicated cases for 5–7 days. This short course is endorsed as a strong recommendation by the guideline. 19
• Evidence shows that a 5–7‑day regimen is as effective as 10–14‑day courses and significantly reduces adverse events. 19

Adjunctive Symptomatic Therapies

Benefits vs. Harms of Antibiotic Therapy

• Absolute benefit is modest: clinical cure/improvement at 7–15 days occurs in 86 % of placebo‑treated patients versus 91 % of those receiving antibiotics (Number Needed to Treat = 18 for rapid cure). This reflects moderate‑quality evidence. 20
• Adverse effects are common, occurring in 15–40 % of treated adults (Number Needed to Harm = 8), primarily gastrointestinal symptoms, rash, and allergic reactions. Evidence is moderate to high quality. [19][20]
• Amoxicillin‑clavulanate carries a higher rate of gastrointestinal side effects compared with other agents, necessitating a risk‑benefit assessment when selecting therapy.

Diagnostic and Imaging Recommendations

• Do not prescribe antibiotics for viral rhinosinusitis, defined as symptoms lasting <10 days without worsening, because most acute rhinosinusitis is viral and self‑limited. 20
• Routine CT or other imaging is not indicated for uncomplicated acute bacterial rhinosinusitis; imaging should be reserved for suspected complications (e.g., orbital or intracranial extension) or chronic disease evaluation. 20

First‑Line Management of Acute Bacterial Rhinosinusitis in Adults

Decision to Treat vs. Watchful Waiting

• Watchful waiting is the preferred initial approach for any adult with uncomplicated acute bacterial rhinosinusitis (ABRS) when reliable follow‑up within 7 days can be ensured, because 80–90 % of patients improve spontaneously within 7–15 days without antibiotics (American Academy of Otolaryngology–Head and Neck Surgery) 22.
• Antibiotics should be reserved for patients who meet any of the following criteria:
  (Both American Academy of Otolaryngology–Head and Neck Surgery and Annals of Internal Medicine) 22, 23.
• Do not prescribe antibiotics for viral rhinosinusitis (symptoms < 10 days without worsening), as the majority of acute rhinosinusitis is viral and self‑limited (Annals of Internal Medicine) 23.

First‑Line Antibiotic Selection

• Standard‑dose amoxicillin alone is recommended for uncomplicated ABRS in adults without risk factors for resistant organisms; it targets Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis (American Academy of Otolaryngology–Head and Neck Surgery) 22; pathogen prevalence data from American Family Physician 24.
• Amoxicillin is preferred because of proven effectiveness, safety, low cost, and a narrow microbiologic spectrum (American Academy of Otolaryngology–Head and Neck Surgery) 22.
• High‑dose amoxicillin‑clavulanate (2 g twice daily) should be used when any resistance risk factor is present, including recent antibiotic use (within past month), age > 65 years, moderate‑to‑severe or protracted symptoms, and comorbidities such as diabetes or immunocompromise (American Academy of Otolaryngology–Head and Neck Surgery; Annals of Internal Medicine) 22, 23.

Alternatives for Penicillin Allergy

• For documented penicillin allergy, prescribe doxycycline as the first alternative (American Academy of Otolaryngology–Head and Neck Surgery; Annals of Internal Medicine) 22, 23, 24.
• If doxycycline is unsuitable, a respiratory fluoroquinolone (levofloxacin or moxifloxacin) may be used (American Academy of Otolaryngology–Head and Neck Surgery; Annals of Internal Medicine) 22, 23.
• For non‑type I hypersensitivity reactions, a combination of clindamycin plus a third‑generation oral cephalosporin (cefixime or cefpodoxime) is appropriate (American Academy of Otolaryngology–Head and Neck Surgery; Journal of Allergy and Clinical Immunology) 22, 25.

Duration of Therapy

• Treat ABRS for 5–7 days; this short course is as effective as 10–14‑day regimens and markedly reduces adverse effects (American Academy of Otolaryngology–Head and Neck Surgery) 22.
• Avoid unnecessarily prolonged courses (10–14 days) because they increase side‑effects without improving outcomes (American Academy of Otolaryngology–Head and Neck Surgery) 22.

Management of Treatment Failure

• Reassess the patient at 72 hours if symptoms worsen or fail to improve (Journal of Allergy and Clinical Immunology) 25.
• If no improvement after 3–5 days of initial amoxicillin, switch to high‑dose amoxicillin‑clavulanate (if not already used) or to a second‑line agent such as cefuroxime, cefpodoxime, cefdinir, or a respiratory fluoroquinolone (Journal of Allergy and Clinical Immunology) 25.

Adjunctive Symptomatic Therapies

• All patients should receive intranasal saline irrigation, analgesics (acetaminophen or ibuprofen), and intranasal corticosteroids (American Academy of Otolaryngology–Head and Neck Surgery) 22; intranasal steroids provide a modest benefit (NNT = 14).
• Oral or topical decongestants may be used for nasal congestion, but topical agents should be limited to ≤3 days to prevent rebound congestion (American Academy of Otolaryngology–Head and Neck Surgery) 22.
• Antihistamines and oral corticosteroids should not be used routinely because they offer no symptom benefit and add unnecessary side‑effects (American Academy of Otolaryngology–Head and Neck Surgery) 22.

Benefits vs. Harms of Antibiotic Therapy

• The absolute benefit of antibiotics is modest: clinical cure or improvement at 7–15 days occurs in 86 % of placebo‑treated adults versus 91 % of those receiving antibiotics, yielding a Number Needed to Treat (NNT) of 18 for faster cure (≈5–6 additional patients per 100) (American Academy of Otolaryngology–Head and Neck Surgery) 22.
• Adverse effects are common, occurring in 15–40 % of treated adults (primarily gastrointestinal symptoms, rash, or allergic reactions), with a Number Needed to Harm (NNH) of 8 (≈13 additional patients per 100 experience side‑effects) (Journal of Allergy and Clinical Immunology) 25.

Imaging Recommendations

• Routine CT or sinus radiography is not indicated for uncomplicated ABRS; imaging should be reserved for suspected complications (e.g., orbital or intracranial extension) or for evaluation of chronic disease (Annals of Internal Medicine) 23.

Levofloxacin Use in Acute Bacterial Sinusitis – Evidence‑Based Recommendations

Indications for Levofloxacin (Second‑Line Therapy)

• Reserve respiratory fluoroquinolones (levofloxacin or moxifloxacin) for sinusitis involving high‑risk anatomic sites—frontal, fronto‑ethmoidal, or sphenoidal sinuses—where complications such as meningitis, orbital cellulitis, or intracranial extension are more likely (American Society of Clinical Microbiology & Infectious Diseases guideline; conditional recommendation) 26, 27, 28, 29.

• Use levofloxacin only after failure of first‑line therapy (amoxicillin‑clavulanate or a cephalosporin) for maxillary sinusitis, and only after bacteriologic or radiologic confirmation of persistent infection (American Society of Clinical Microbiology & Infectious Diseases guideline; conditional recommendation) 26, 27, 28, 29.

• Levofloxacin is an acceptable alternative for adults with documented penicillin allergy, together with doxycycline (American Academy of Otolaryngology–Head and Neck Surgery guideline; conditional recommendation) 30.

First‑Line Antibiotic Choice

• Amoxicillin with or without clavulanate remains the first‑line agent for most adults with acute bacterial rhinosinusitis because of its proven efficacy, safety, low cost, and narrow microbiologic spectrum (AAO‑HNS guideline; strong recommendation) 30.

• When resistance risk factors are present—recent antibiotic use (< 1 month), age > 65 years, moderate‑to‑severe symptoms, comorbidities, or residence in an area where > 10 % of Streptococcus pneumoniae are penicillin‑nonsusceptible—high‑dose amoxicillin‑clavulanate (2 g twice daily) should be employed (AAO‑HNS guideline; strong recommendation) 30.

Dosing and Duration of Levofloxacin

• A 5‑day high‑dose regimen (750 mg once daily) is FDA‑approved and non‑inferior to the traditional 10‑day 500 mg regimen, providing comparable clinical success while reducing exposure and improving compliance (AAO‑HNS guideline; conditional recommendation) 30.

• Overall treatment courses of 5–7 days are as effective as 10–14 day courses for acute bacterial sinusitis and significantly lower the incidence of adverse events (AAO‑HNS guideline; strong recommendation) 30.

Pediatric Considerations

• For children, amoxicillin (or high‑dose amoxicillin‑clavulanate when risk factors exist) remains the first‑line therapy for acute bacterial sinusitis (American Family Physician guideline; strong recommendation) 31.

• In penicillin‑allergic children, cefdinir, cefuroxime, or cefpodoxime are the preferred alternatives (American Family Physician guideline; strong recommendation) 31.

• Fluoroquinolones are generally avoided in the pediatric population because of concerns about musculoskeletal toxicity, although levofloxacin has been studied in pediatric respiratory infections (Pediatrics journal; conditional recommendation) 32.

Diagnostic Criteria for Acute Bacterial Rhinosinusitis

• Confirm bacterial rhinosinusitis when symptoms persist ≥ 10 days, or when there is severe presentation (fever > 39 °C + purulent nasal discharge ≥ 3 days), or a pattern of double worsening (AAO‑HNS guideline; strong recommendation) 30.

Management of Resistance Risk Factors

• If resistance risk factors are identified, switch from standard amoxicillin to high‑dose amoxicillin‑clavulanate rather than proceeding directly to a fluoroquinolone (AAO‑HNS guideline; strong recommendation) 30.

Imaging Recommendations

• Routine computed tomography is not indicated for uncomplicated acute bacterial sinusitis; reserve imaging for cases where complications are suspected (AAO‑HNS guideline; strong recommendation) 30.

Common Pitfalls & Recommendations

Antibiotic Selection and Safety in Penicillin‑Allergic Patients with Acute Bacterial Sinusitis

Cephalosporin Use and Allergy Cross‑Reactivity

• In patients with non‑type I penicillin hypersensitivity (e.g., not anaphylaxis, angioedema, or urticaria), second‑ and third‑generation oral cephalosporins (cef dinir, cef uroxime, cef podoxime) can be used safely because the risk of serious allergic reaction is essentially zero and comparable to that in non‑allergic individuals【33】.
• For broader coverage, a combination of clindamycin plus a third‑generation oral cephalosporin (cef ifixime or cef podoxime) is an acceptable alternative to ensure activity against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis【33】.

Resistance Concerns for Macrolides and TMP‑SMX

• Macrolide antibiotics (azithromycin, clarithromycin) are not recommended as first‑line therapy because macrolide resistance in S. pneumoniae exceeds 40 % in the United States【34】.
• Trimethoprim‑sulfamethoxazole should also be avoided; resistance rates are approximately 50 % for S. pneumoniae and 27 % for H. influenzae【34】.

Adjunctive Symptomatic Therapies

• Analgesics such as acetaminophen or ibuprofen are recommended for pain and fever control in acute bacterial sinusitis【34】.

Avoidance of Ineffective Medications

• Routine use of antihistamines or oral corticosteroids provides no symptomatic benefit and adds unnecessary side effects; therefore they should be avoided in the management of acute bacterial sinusitis【35】.

Pediatric Antibiotic Recommendations

• In penicillin‑allergic children, the preferred oral alternatives are cef dinir, cef uroxime, or cef podoxime, reflecting the same safety profile regarding cross‑reactivity as in adults【33】.

Table: Common Pitfalls and Evidence‑Based Recommendations

All bullet points are supported by the cited references indicated in brackets.

Management of Acute Bacterial Rhinosinusitis in Adults

Diagnosis

• Persistent purulent nasal discharge, nasal obstruction, or facial pain/pressure lasting ≥ 10 days without improvement defines acute bacterial rhinosinusitis (ABRS) in adults. – American Academy of Otolaryngology‑Head and Neck Surgery 36

Initial Management: Watchful Waiting vs. Immediate Antibiotics

Watchful Waiting (Preferred First‑Line)

• In any adult with uncomplicated ABRS who can be reliably followed up within 7 days, a watchful‑waiting approach without antibiotics is recommended, irrespective of symptom severity. – AAO‑HNS 37
• Expected spontaneous improvement occurs in 80–90 % of patients within 7–15 days; the absolute benefit of antibiotics is modest (placebo 86 % vs. antibiotics 91 %; NNT = 18). – AAO‑HNS 36
• Adverse effects are reported in 15–40 % of antibiotic‑treated patients (NNT = 8 for harm), mainly gastrointestinal. – AAO‑HNS 36

Symptomatic Relief During Watchful Waiting

• Analgesics (acetaminophen or ibuprofen) for pain and fever. – AAO‑HNS 36
• Intranasal saline irrigation to clear mucus. – AAO‑HNS 36
• Intranasal corticosteroids provide a modest benefit after 15 days (NNT = 14). – AAO‑HNS 36
• Oral or topical decongestants for congestion (topical use ≤ 3 days to avoid rebound). – AAO‑HNS 36
• Antihistamines and oral corticosteroids are not recommended routinely because they show no benefit and add side‑effects. – AAO‑HNS [36][38]

When Immediate Antibiotics Are Appropriate

• Severe presentation (fever > 39 °C with purulent discharge or facial pain for ≥ 3–4 days).
• High‑risk patients (age > 65 years, recent antibiotic use, moderate‑to‑severe symptoms, comorbidities such as diabetes or immunocompromise, recent hospitalization).
• Patient preference after shared decision‑making. – AAO‑HNS 37

Antibiotic Selection

First‑Line Agents

• Standard‑dose amoxicillin alone is the preferred first‑line agent for most adults without resistance risk factors. – AAO‑HNS 36
• Amoxicillin ± clavulanate (including high‑dose amoxicillin‑clavulanate 2 g twice daily) is recommended when β‑lactamase‑producing H. influenzae or M. catarrhalis are a concern or when resistance risk factors are present. – AAO‑HNS [36][39]

Alternatives for Penicillin‑Allergic Patients

• Doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin). – AAO‑HNS 36
• For non‑type I hypersensitivity, clindamycin plus a third‑generation oral cephalosporin (cefixime or cefpodoxime) is acceptable. – AAO‑HNS 36

Agents to Avoid

• Macrolides (azithromycin, clarithromycin) and trimethoprim‑sulfamethoxazole due to > 40 % resistance in S. pneumoniae.

Duration of Therapy

• 5–7 days of antibiotic therapy is sufficient for uncomplicated ABRS and is as effective as 10–14 day courses while reducing adverse events. – AAO‑HNS 36

Reassessment & Management of Treatment Failure

• Reassess patients 72 hours to 7 days after initiation if symptoms worsen or fail to improve. – AAO‑HNS 36
  
  • Confirm the ABRS diagnosis. – AAO‑HNS 36
  • Exclude complications (orbital cellulitis, intracranial extension). – AAO‑HNS 39
  • Consider alternative diagnoses. – AAO‑HNS 36
• If no improvement after 3–5 days of standard amoxicillin, switch to high‑dose amoxicillin‑clavulanate (if not already used) or consider second‑line agents such as cefuroxime, cefpodoxime, cefdinir, or a respiratory fluoroquinolone.

Imaging Recommendations

• Routine CT or plain radiographs are not indicated for uncomplicated ABRS. – AAO‑HNS 38
• Imaging is reserved for suspected complications (e.g., orbital cellulitis, intracranial extension) or failure to improve after 21–28 days of appropriate therapy. – AAO‑HNS [39][36]

Common Pitfalls (Evidence‑Based Recommendations)

Antibiotic Management of Acute Bacterial Sinusitis in Adults with Penicillin and Sulfonamide Allergy

Indications for Initiating Antibiotics

• Persistent symptoms for ≥ 10 days, severe presentation (fever > 39 °C + purulent nasal discharge or facial pain for ≥ 3 consecutive days), or “double worsening” (initial improvement followed by relapse 5–10 days after onset) indicate bacterial sinusitis and justify antibiotic therapy【40】.

First‑Line Antibiotic Choice

• Doxycycline is the preferred first‑line oral agent for adults with documented penicillin allergy (and sulfonamide allergy) suffering acute bacterial sinusitis【40】.

Alternative Antibiotic Options

• Respiratory fluoroquinolones (levofloxacin or moxifloxacin) are acceptable alternatives when doxycycline cannot be used【40】.
• Reserve fluoroquinolones for high‑risk sinus locations (frontal, fronto‑ethmoidal, or sphenoidal) where complications such as meningitis or orbital cellulitis are more likely【41】.
• Fluoroquinolones are also appropriate after failure of first‑line therapy【41】.

Use of Cephalosporins (When Allergy Allows)

• If the penicillin allergy is non‑type I (i.e., not anaphylaxis, angioedema, or urticaria), second‑ or third‑generation oral cephalosporins (e.g., cefdinir, cefuroxime, cefpodoxime) are safe and carry essentially zero risk of serious allergic reaction【40】.
• For broader coverage, a combination of clindamycin with a third‑generation cephalosporin (e.g., cefixime or cefpodoxime) may be used【40】.

Duration of Therapy

• A short course of 5–7 days is as effective as longer 10–14 day regimens and markedly reduces adverse‑effect rates【40】.

Follow‑up and Management of Treatment Failure

• Reassess the patient at 72 hours if symptoms worsen or fail to improve【42】.
• If no clinical improvement after 3–5 days of the initial regimen, consider switching to a respiratory fluoroquinolone (if not already used) or another second‑line agent【42】.

Adjunctive Symptomatic Care (Supportive Therapy)

• Intranasal saline irrigation should be offered to all patients to aid mucus clearance【40】.
• Analgesics such as acetaminophen or ibuprofen are recommended for pain and fever control【40】.

Imaging Recommendations

• Routine imaging is not indicated for uncomplicated acute bacterial sinusitis; reserve imaging for cases where complications are suspected (e.g., orbital cellulitis, intracranial extension)【40】.

Antibiotic Initiation and Management for Acute Bacterial Sinusitis in Patients Allergic to Penicillin and Sulfonamides

Diagnostic Criteria for Initiating Antibiotics

• In adults, prescribe antibiotics only when persistent symptoms (purulent nasal discharge, nasal obstruction, or facial pain/pressure) last ≥ 10 days without improvement【43】【44】.
• Severe presentation—fever > 39 °C (102.2 °F) together with purulent nasal discharge or facial pain for ≥ 3 consecutive days—also warrants antibiotic therapy【43】【44】.

First‑Line Antibiotic Dosing (Allergy‑Specific Choice)

• Doxycycline is the recommended first‑line oral agent for patients with documented penicillin and sulfonamide allergies; the standard adult regimen is 100 mg twice daily【45】.

Resistance‑Based Recommendations for Alternative Agents

• Macrolides (azithromycin, clarithromycin) should be avoided because ≥ 40 % of Streptococcus pneumoniae isolates in the United States are resistant, making them ineffective in penicillin‑allergic patients【43】【44】.

Indications for Specialist Referral

• Refer to otolaryngology or infectious‑disease specialists when suspected complications (e.g., orbital swelling, severe headache, photophobia, or neurologic findings) are present【43】.
• Consider referral for patients with recurrent sinusitis episodes that require evaluation for underlying predisposing factors【45】.

Management of Acute Bacterial Sinusitis: Diagnostic Criteria, Imaging, and Use of Fluoroquinolones in Penicillin‑Allergic Patients

Penicillin‑Allergy Considerations

• In adults with a documented penicillin allergy, doxycycline is the preferred first‑line alternative; levofloxacin (or moxifloxacin) may be employed only when doxycycline is contraindicated or not tolerated. 46

Diagnostic Criteria for Initiating Antibiotic Therapy

• Antibiotics should be started in patients with acute bacterial sinusitis who meet any of the following criteria:

Imaging Recommendations

• Routine computed‑tomography (CT) or plain radiographs are not indicated for uncomplicated acute bacterial sinusitis; imaging should be reserved for suspected complications (e.g., orbital cellulitis, intracranial extension) or when there is no clinical improvement after 21–28 days of appropriate therapy. 46

Stewardship Pitfall to Avoid

• Prescribing antibiotics for viral rhinosinusitis—i.e., when symptoms are < 10 days without worsening—should be avoided. 46

Antibiotic Management and Assessment of Acute Bacterial Rhinosinusitis with Suppurative Complications

Diagnostic Criteria for Initiating Antibiotics

• Persistent sinus symptoms lasting more than 10 days with clinical worsening strongly suggests acute bacterial rhinosinusitis rather than a viral URI, indicating the need for antimicrobial therapy. 47
• The presence of a tonsillar abscess (a suppurative complication) together with moderate‑to‑severe symptomatology qualifies the infection as high‑risk and supports the use of high‑dose amoxicillin‑clavulanate as first‑line treatment. 48

Reassessment and Monitoring (72‑Hour Check‑Point)

• At 72 hours after starting antibiotics, clinicians should reassess for lack of improvement or clinical deterioration; this includes confirming bacterial sinusitis and actively ruling out complications such as orbital cellulitis (periorbital swelling, vision changes, ophthalmoplegia) or intracranial extension (severe headache, altered mental status, focal neurologic deficits). 47

Imaging Recommendations

• Routine computed tomography (CT) of the sinuses is not indicated for uncomplicated acute bacterial rhinosinusitis, even when a tonsillar abscess is present, provided the patient can swallow and shows no orbital or neurologic signs. 47
• CT imaging should be reserved for:

Management of Suppurative Complications

• If the tonsillar abscess enlarges or the patient develops dysphagia, odynophagia, or an inability to swallow, an immediate referral to otolaryngology for possible incision and drainage is warranted. 48
• Untreated tonsillar abscesses can progress to more severe infections, including peritonsillar abscess, parapharyngeal space infection, or descending necrotizing mediastinitis, underscoring the need for prompt antimicrobial coverage and close monitoring. 48